$3.06
+0.11 (+3.73%)
Open$2.90
Previous Close$2.95
Day High$3.08
Day Low$2.85
52W High$4.53
52W Low$1.73
Volume—
Avg Volume538.3K
Market Cap97.00M
P/E Ratio0.76
EPS$3.44
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+322.5% upside
Current
$3.06
$3.06
Target
$12.93
$12.93
$7.67
$12.93 avg
$16.62
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 73.56M | 78.10M | 15.02M |
| Net Income | 7.92M | 7.57M | -500,427 |
| Profit Margin | 10.8% | 10.2% | -3.3% |
| EBITDA | -45,156,683 | -45,549,850 | -867,054 |
| Free Cash Flow | — | — | -309,659 |
| Rev Growth | -5.8% | -5.8% | +23.3% |
| Debt/Equity | 1.19 | 1.19 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |